Staar Surgical downgraded to Neutral from Outperform at Mizuho

Mizuho downgraded Staar Surgical (STAA) to Neutral from Outperform with a price target of $17, down from $45. The firm cites the “disappointing” Q4 report, lower than expected 2025 guide, and pulling of Staar’s “Vision 2026” plan for the downgrade. The sharpness of the correction in China sales in Q4 and “very modest” first half of 2025 outlook is linked to a push-out of $28M in distributor revenue which is underpinned by the weak underlying consumer backdrop, the analyst tells investors in a research note. Mizuho has a more cautious near-term outlook for Staar Surgical.